JP2022548057A5 - - Google Patents
Info
- Publication number
- JP2022548057A5 JP2022548057A5 JP2022516173A JP2022516173A JP2022548057A5 JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5 JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg1
- amino acid
- acid sequence
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025112447A JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1913079.8A GB201913079D0 (en) | 2019-09-11 | 2019-09-11 | Treatment and prevention of cancer using her3 antigen-binding molecules |
| GB1913079.8 | 2019-09-11 | ||
| PCT/EP2020/075319 WO2021048274A1 (en) | 2019-09-11 | 2020-09-10 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112447A Division JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548057A JP2022548057A (ja) | 2022-11-16 |
| JP2022548057A5 true JP2022548057A5 (https=) | 2023-09-19 |
| JP7708741B2 JP7708741B2 (ja) | 2025-07-15 |
Family
ID=68241208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516173A Active JP7708741B2 (ja) | 2019-09-11 | 2020-09-10 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
| JP2025112447A Pending JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112447A Pending JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11208498B2 (https=) |
| EP (2) | EP3818086B1 (https=) |
| JP (2) | JP7708741B2 (https=) |
| KR (1) | KR20220086554A (https=) |
| CN (2) | CN116059347A (https=) |
| AU (1) | AU2020347473A1 (https=) |
| BR (1) | BR112022004474A8 (https=) |
| CA (1) | CA3149853A1 (https=) |
| DK (1) | DK3818086T3 (https=) |
| ES (1) | ES2896921T3 (https=) |
| GB (1) | GB201913079D0 (https=) |
| MX (1) | MX2022002977A (https=) |
| PL (1) | PL3818086T3 (https=) |
| PT (1) | PT3818086T (https=) |
| TW (1) | TWI883044B (https=) |
| WO (1) | WO2021048274A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3433273T (pt) | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| SG11201809316XA (en) * | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| KR20240125061A (ko) | 2017-03-27 | 2024-08-19 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN114790462B (zh) * | 2021-01-25 | 2023-10-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向bcma的嵌合抗原受体及其应用 |
| CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
| EP4304636A1 (en) * | 2021-03-11 | 2024-01-17 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
| TW202313987A (zh) * | 2021-06-03 | 2023-04-01 | 荷蘭商美勒斯公司 | 用於測定nrg1融合多核苷酸的液態檢體測定法 |
| JP2024523001A (ja) * | 2021-06-03 | 2024-06-25 | メルス ナムローゼ フェンノートシャップ | 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法 |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| US20250136712A1 (en) | 2021-08-13 | 2025-05-01 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| JP2024536719A (ja) * | 2021-09-03 | 2024-10-08 | キャンサー・リサーチ・テクノロジー・リミテッド | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| CN120417924A (zh) | 2022-12-07 | 2025-08-01 | 蜂鸟生物科技私人有限公司 | 治疗和预防癌症的组合疗法 |
| WO2024147097A1 (en) | 2023-01-03 | 2024-07-11 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| EP4687972A1 (en) | 2023-04-06 | 2026-02-11 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| KR20260022498A (ko) | 2023-04-14 | 2026-02-19 | 허밍버드 바이오사이언스 피티이. 엘티디. | 암의 치료 및 예방을 위한 조합물 |
| WO2025057173A2 (en) * | 2023-09-14 | 2025-03-20 | B.G. Negev Technologies And Applications Ltd. | Ligand-based chimeric antigen receptors and uses thereof |
| WO2025056781A1 (en) | 2023-09-15 | 2025-03-20 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3-binding molecules |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| MY152068A (en) * | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| EP2571901B1 (en) * | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Biological materials related to her3 |
| CN104105709A (zh) * | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 抗her3的结构域ii的表皮生长因子受体3(her3)抗体 |
| US20130259867A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| EP3085781A1 (en) | 2013-12-19 | 2016-10-26 | National Cancer Center | Novel fusion gene as factor responsible for stomach cancer |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3679063A4 (en) | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
-
2019
- 2019-09-11 GB GBGB1913079.8A patent/GB201913079D0/en not_active Ceased
-
2020
- 2020-09-10 AU AU2020347473A patent/AU2020347473A1/en active Pending
- 2020-09-10 CN CN202211117480.0A patent/CN116059347A/zh active Pending
- 2020-09-10 PT PT207805722T patent/PT3818086T/pt unknown
- 2020-09-10 EP EP20780572.2A patent/EP3818086B1/en active Active
- 2020-09-10 EP EP21180956.1A patent/EP3943509A1/en active Pending
- 2020-09-10 JP JP2022516173A patent/JP7708741B2/ja active Active
- 2020-09-10 KR KR1020227011181A patent/KR20220086554A/ko active Pending
- 2020-09-10 BR BR112022004474A patent/BR112022004474A8/pt unknown
- 2020-09-10 MX MX2022002977A patent/MX2022002977A/es unknown
- 2020-09-10 CA CA3149853A patent/CA3149853A1/en active Pending
- 2020-09-10 ES ES20780572T patent/ES2896921T3/es active Active
- 2020-09-10 WO PCT/EP2020/075319 patent/WO2021048274A1/en not_active Ceased
- 2020-09-10 DK DK20780572.2T patent/DK3818086T3/da active
- 2020-09-10 PL PL20780572T patent/PL3818086T3/pl unknown
- 2020-09-10 TW TW109131184A patent/TWI883044B/zh active
- 2020-09-10 CN CN202080009114.6A patent/CN113347994B/zh active Active
-
2021
- 2021-01-20 US US17/153,705 patent/US11208498B2/en active Active
- 2021-11-24 US US17/535,313 patent/US20220153870A1/en active Pending
-
2025
- 2025-07-02 JP JP2025112447A patent/JP2025143396A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548057A5 (https=) | ||
| Griffin et al. | Targeting neurotrophin signaling in cancer: The renaissance | |
| JP2022533957A5 (https=) | ||
| Yin et al. | ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway | |
| IL270852A (en) | Molecules that bind at the site of egfr and c – met - fibronectin type iii | |
| Xu et al. | MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| IL287940B1 (en) | Fgfr inhibitors and methods of use thereof | |
| JP2022088662A5 (https=) | ||
| Wang et al. | Molecular mechanisms of chemoresistance in oral cancer | |
| EP4512478A3 (en) | Treatment of cancer | |
| JP2011521618A5 (https=) | ||
| RU2007132876A (ru) | Антитела к dr5 и их применения | |
| JP2017503480A5 (https=) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| RU2019143403A (ru) | Комбинированные терапии для лечения онкологических заболеваний | |
| JP2024536719A5 (https=) | ||
| Li et al. | Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer | |
| Gafton et al. | Hepatocellular carcinoma: insight in the biological treatment beyond sorafenib | |
| JP2022551495A5 (https=) | ||
| RU2015154985A (ru) | Способы лечения рака | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения | |
| Oghenemaro et al. | Role of glutaminyl-peptide cyclo-transferase-like protein (QPCTL) in cancer: From molecular mechanisms to immunotherapy | |
| JP2025508695A5 (https=) | ||
| Radford et al. | Targeted and immunotherapy approaches in HER2-positive gastric and gastroesophageal junction adenocarcinoma: a new era |